ArticleFrontiers in immunology2021

Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients.

Maria Giovanna Danieli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.